We are live on ! Find out more
EFM

E Fund Management Portfolio holdings

AUM $4.46B
This Fund
S&P 500
This Quarter Est. Return
-2.75%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.99B
AUM Growth
+$45.8M
Cap. Flow
+$213M
Cap. Flow %
10.7%
Top 10 Hldgs %
56.29%
Holding
416
New
63
Increased
249
Reduced
78
Closed
21

Top Buys

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$39.6M
2
NVDA icon
NVIDIA
NVDA
+$38M
3
MSFT icon
Microsoft
MSFT
+$36.6M
4
AMZN icon
Amazon
AMZN
+$12.2M
5
YUMC icon
Yum China
YUMC
+$10.6M

Top Sells

Rank Stock Value
1
PDD icon
Pinduoduo
PDD
+$45M
2
FUTU icon
Futu Holdings
FUTU
+$16.1M
3
TSM icon
TSMC
TSM
+$13.2M
4
AMAT icon
Applied Materials
AMAT
+$7.81M
5
TME icon
Tencent Music
TME
+$4.18M

Sector Composition

Rank Sector Weight
1 Technology 40.04%
2 Consumer Discretionary 27.82%
3 Communication Services 8.98%
4 Healthcare 6.75%
5 Financials 5.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCRX icon
376
BioCryst Pharmaceuticals
BCRX
$2.51B
$125K 0.01%
16,612
-7,226
-30% -$54.9K
F icon
377
Ford
F
$55.3B
$101K 0.01%
+10,208
New +$109K
IBRX icon
378
ImmunityBio
IBRX
$8.53B
$99.6K 0.01%
38,900
+9,622
+33% +$40.1K
EBS icon
379
Emergent Biosolutions
EBS
$303M
$97.9K ﹤0.01%
+10,238
New +$93.9K
KURA icon
380
Kura Oncology
KURA
$1.13B
$89.7K ﹤0.01%
+10,301
New +$148K
COGT icon
381
Cogent Biosciences
COGT
$6.02B
$88.8K ﹤0.01%
+11,380
New +$113K
HUMA icon
382
Humacyte
HUMA
$181M
$82.5K ﹤0.01%
16,345
+476
+3% +$2.35K
ALT icon
383
Altimmune
ALT
$605M
$80.5K ﹤0.01%
11,159
+1,149
+11% +$8.78K
ANNX icon
384
Annexon
ANNX
$942M
$79.2K ﹤0.01%
15,447
+4,086
+36% +$25.1K
IRWD icon
385
Ironwood Pharmaceuticals
IRWD
$682M
$74.2K ﹤0.01%
16,746
-8,739
-34% -$35.5K
RLAY icon
386
Relay Therapeutics
RLAY
$4.11B
$72.7K ﹤0.01%
17,654
+6,104
+53% +$33.2K
ALLO icon
387
Allogene Therapeutics
ALLO
$698M
$55.4K ﹤0.01%
25,992
+5,629
+28% +$13.9K
ERAS icon
388
Erasca
ERAS
$6.31B
$37.2K ﹤0.01%
14,838
-79
-0.5% -$217
SANA icon
389
Sana Biotechnology
SANA
$1.18B
$36.2K ﹤0.01%
22,202
+1,612
+8% +$4.81K
ABUS icon
390
Arbutus Biopharma
ABUS
$1B
$34K ﹤0.01%
+10,385
New +$38.2K
SVRA icon
391
Savara
SVRA
$1.08B
$31.9K ﹤0.01%
10,399
-403
-4% -$1.41K
TSHA icon
392
Taysha Gene Therapies
TSHA
$1.88B
$30.9K ﹤0.01%
+17,844
New +$37K
SGMO
393
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$25.4K ﹤0.01%
+24,853
New +$45.4K
AKBA icon
394
Akebia Therapeutics
AKBA
$243M
$24.2K ﹤0.01%
+12,716
New +$22.1K
SCLX icon
395
Scilex Holding
SCLX
$38.2M
$13.4K ﹤0.01%
898
– –
AGIO icon
396
Agios Pharmaceuticals
AGIO
$1.99B
– –
-5,751
Closed -$256K
APGE icon
397
Apogee Therapeutics
APGE
$10.2B
– –
-3,506
Closed -$206K
APLT
398
DELISTED
Applied Therapeutics
APLT
– –
-10,232
Closed -$87K
ARWR icon
399
Arrowhead Research
ARWR
$12B
– –
-11,438
Closed -$222K
BEAM icon
400
Beam Therapeutics
BEAM
$3.03B
– –
-12,020
Closed -$294K
13 14 15
16
17

Similar funds

ACM
Advent Capital Management New York $4.46B AUM 0.73% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
MAM
Magellan Asset Management Sydney, Australia $4.47B AUM 4.2% 1-Year Est. Return
AP
Americana Partners Houston, Texas $4.44B AUM 29.45% 1-Year Est. Return
BP
BC Partners New York $4.43B AUM 49.12% 1-Year Est. Return
WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.48B AUM 24.77% 1-Year Est. Return
AOI
Auto-Owners Insurance Lansing, Michigan $4.43B AUM 30.05% 1-Year Est. Return
WA
WestEnd Advisors Charlotte, North Carolina $4.49B AUM 19.44% 1-Year Est. Return

E Fund Management's Q4 2024 Portfolio in Review

As of Q4 2024, E Fund Management held 416 positions worth $1.99B, up 2.4% from $1.95B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

E Fund Management deployed $213M of net new capital in Q4 2024, opening 63 new positions and adding to 249 existing holdings. Its largest new stake was Yum China: 222,743 shares worth $10.7M.

By sector, the portfolio is most concentrated in Technology at 40% of assets, up from 31% a quarter earlier, followed by Consumer Discretionary and Communication Services.

On the sell side, the largest reduction was Pinduoduo, an estimated $45M trimmed.

  • E Fund Management's largest Q4 2024 buy was Yum China: 222,743 shares worth $10.7M.
  • E Fund Management added most to Apple in Q4 2024, an estimated $39.6M increase.
  • E Fund Management's biggest Q4 2024 reduction was Pinduoduo, cutting an estimated $45M.
  • E Fund Management fully exited Lufax Holding in Q4 2024, selling an estimated $3.9M.
  • E Fund Management's ten largest holdings make up 56% of its $1.99B portfolio in Q4 2024.
  • E Fund Management opened 63 new positions and closed 21 in Q4 2024.
  • E Fund Management's portfolio value rose 2.4% quarter-over-quarter to $1.99B.

Based on E Fund Management's 13F filing for Q4 2024, filed 7 Feb 2025.